A stent for vascular interventions having a hybrid open cell geometry. Variants of the stent include bare metal stents and drug-eluting stents. Embodiments of the stent include end projections for radiopaque markers or a discontinuous partial radiopaque coating on low-stress or low-strain regions of the peripheral stent. The stents of the invention are characterized by having thin walls, nested rows of struts, high expansion ratio, high and uniform radial force over entire diametric size and length of device, crush resistance up to and including about 90% of its fully expanded diameter, high fatigue resistance and high corrosion resistance.

A stent for vascular interventions having a hybrid open cell geometry. Variants of the stent include bare metal stents and drug-eluting stents. Embodiments of the stent include end projections for radiopaque markers or a discontinuous partial radiopaque coating on low-stress or low-strain regions of the peripheral stent. The stents of the invention are characterized by having thin walls, nested rows of struts, high expansion ratio, high and uniform radial force over entire diametric size and length of device, crush resistance up to and including about 90% of its fully expanded diameter, high fatigue resistance and high corrosion resistance.

The present disclosure relates to the field of implantable intraocular drug delivery devices. In particular, the present disclosure relates to intraocular drug delivery devices integrated into a capsular tension ring (“CTR”) that is designed for implantation in the capsule or the ciliary sulcus during a cataract extraction and intraocular lens implantation procedure.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

This document discusses, among other things, an apparatus comprising a lacrimal implant insertable at least partially into a lacrimal punctum. The lacrimal implant comprises an implant core, and an implant body. The implant body includes a cavity sized and shaped to receive the implant core. At least one of the implant core and the implant cavity includes a detection device configured to allow automatic detection of the lacrimal implant with a separate detector device.

A non-occlusive intravascular device for local application of a therapeutic agent to a selected segment of a lumenal wall of a blood vessel without applying radial force on the wall. The device comprises a radially expandable/collapsible flexible scaffold of an open-skeletal structure and a flexible outer surface capable of conforming to the lumenal wall without applying radial force thereon and a controllable mechanism for expanding and collapsing the scaffold. The therapeutic agent is loaded and carried on the outer surface of the scaffold. Also provided are a method and a system for delivering a therapeutic agent to a selected segment within a blood vessel.

An upgradable intraocular platform system includes (a) a substrate implantable in an eye; (b) an upgrade interface on the substrate for connection of at least one upgrade component for upgrading the platform system; and (c) a controller for controlling operation of the platform system.

A stent and method of making incorporating flexible, preferably polymeric, connecting elements into the stent wherein these elements connect element(s) across an intervening space. The polymeric connecting elements are designed to fold within the space between the outer diameter of the stent and the inner diameter of the stent.

Described are implantable devices having expandable reservoirs for the sustained release of therapeutic agents. The device is configured to be at least partially implanted in an eye and includes a retention structure and a penetrable element coupled to and extending within at least a portion of the retention structure. A porous drug release mechanism is positioned in fluid communication with an outlet of the device; and a reservoir having a volume configured to contain one or more therapeutic agents is in fluid communication with the outlet through the porous drug release mechanism. The device is at least partially inserted along an axis of insertion. The reservoir enlarges from an insertion configuration having a first three-dimensional shape to an expanded configuration having a second three-dimensional shape, the second three-dimensional shape being eccentrically positioned relative to the axis of insertion.

An adjustable optic device for providing light field information includes: (a) at least one counter electrode; (b) one or more working electrodes; (c) an insulating framework separating the counter electrode from each working electrode; and (d) an electrolyte medium between the counter electrode and the one or more working electrodes. Each working electrode is reversibly transitionable from a stripped state toward a plated state when a plating charge voltage is applied to induce plating with ions from the electrolyte medium. When in the stripped state, the one or more working electrodes are transparent and present a passage through the optic device for transmission of electromagnetic radiation. When in the plated state, the one or more working electrodes are plated with ions from the electrolyte medium to provide a coded aperture in the passage. The coded aperture has a pattern of subapertures for providing light field information.